Home > Cardiology > AHA 2020 > CVD Risk Reduction > No CV benefit from omega 3 in high-risk patients

No CV benefit from omega 3 in high-risk patients

Presented By
Prof. Michael Lincoff, Cleveland Clinic, USA
Conference
AHA 2020
Trial
STRENGTH

Results from the STRENGTH trial did not indicate any primary prevention benefit of high-dose omega-3 in patients with high cardiovascular risk. There was no significant difference versus placebo for the composite outcome of major adverse cardiovascular events in this large randomised controlled trial [1].

Findings from the STRENGTH trial (NCT02104817) were presented by Prof. Michael Lincoff (Cleveland Clinic, USA), and were simultaneously published in JAMA [1,2]. The goal of the placebo-controlled STRENGTH trial was to evaluate the combined omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in patients with dyslipidaemia and high cardiovascular risk. The primary endpoint was a composite of cardiovascular death, non-fatal heart attack, non-fatal stroke, coronary artery revascularisation, and hospitalisation for unstable angina.



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on